SCHEMBL29778381

SCHEMBL29778381

CNC(=O)c1cccc(Cn2cc(CC(C)O)c3cc(-c4cn[nH]c4Cl)ccc3c2=O)c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.41
TNIK Q9UKE5 1/20 0.39
BRD4 O60885 7/20 0.38
YTHDC1 Q96MU7 1/20 0.38
CECR2 Q9BXF3 1/20 0.37
KDM4E B2RXH2 1/20 0.37
GRK2 P25098 1/20 0.37
CYP4F2 P78329 1/20 0.36
CYP4A11 Q02928 1/20 0.36
FSCN1 Q16658 1/20 0.36
SLC7A5 Q01650 1/20 0.36
MKNK1 Q9BUB5 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
TAF1 P21675 1/20 0.35
TDO2 P48775 1/20 0.35
ROCK2 O75116 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24617445 1.00 MAPK1 (0.41) MAPK1TNIKBRD4YTHDC1CECR2
SCHEMBL30656477 0.89 GRK2 (0.37) MAPK1TNIKBRD4YTHDC1CECR2
SCHEMBL29136009 0.89 GRK2 (0.37) MAPK1TNIKBRD4YTHDC1CECR2
SCHEMBL29778456 0.89 MAPK1 (0.42) MAPK1TNIKBRD4YTHDC1CECR2
SCHEMBL24616967 0.89 MAPK1 (0.42) MAPK1TNIKBRD4YTHDC1CECR2
SCHEMBL30656540 0.89 TDO2 (0.40) MAPK1TNIKBRD4CECR2KDM4E
SCHEMBL29135965 0.89 TDO2 (0.40) MAPK1TNIKBRD4CECR2KDM4E
SCHEMBL24617483 0.87 MAPK1 (0.41) MAPK1TNIKBRD4YTHDC1CECR2
SCHEMBL24617466 0.84 MAPK1 (0.39) MAPK1TNIKBRD4YTHDC1CECR2
SCHEMBL29778613 0.84 MAPK1 (0.39) MAPK1TNIKBRD4YTHDC1CECR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 US claimed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 CN claimed
EP-4274825-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2023-11-15 EP claimed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 WO claimed
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 US disclosed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 CN disclosed
EP-4274825-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2023-11-15 EP disclosed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF ROCK2, ROCK1, MYLK3 MAPK1 146/4885TNIK 223/4885BRD4 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.